Föreläsningar och seminarier

Fysiologföreningen: Adrian Newman-Tancredi

2013-09-2514:15 Hillarp Lecture Hall, Retzius väg 8, Campus Solna

The novel pharmacology of antipsychotics: how recent advances point to a key role for serotonin 5-HT1A receptors

Dr. Adrian Newman-Tancredi is a neuropharmacologist with two decades of achievement in industrial "drug hunting". Adrian personally participated in the identification and charac­terization of novel antipsychotics, antidepressants and analgesics at the Servier Research Institute (Paris, France; 1993-2002) and at Pierre Fabre Laboratories (Castres, France; 2002-2010). In 2010, he created an independent neuropharmacology consulting service (NeuroAct Communication) and then co-founded Neurolixis in 2011, a neuroscience-focused bioscience company. He has published extensive analyses of the mechanism of action of antipsychotic drugs and developed the concept of biased receptors agonists with focus on the 5-HT1A receptor. Use of such biased agonists in conjunction with antipsychotic drugs offers a new strategy for treating schizophrenia patients which is now being explored.

Host: Prof. Sven Ove Ögren